Table 3.

Secondary outcomes

	Placebo (n=891)	Co-trimoxazole (n=887)	Incidence rate ratio (95% CI)
Non-fatal hospital admissions	320	296	0·93 (0·79–1·09)
Hospital admission or death	455	418	0·92 (0·80–1·05)
Outpatient treatment	1666	1600	0·96 (0·89–1·03)
Outpatient, hospital admission, or death	2441	2314	0·95 (0·90–1·00)
All pneumonia	682	633	0·93 (0·83–1·04)
Severe pneumonia	200	193	0·97 (0·79–1·18)
All diarrhoea	458	512	1·14 (1·02–1·28)*
Severe diarrhoea	100	125	1·25 (0·95–1·64)
Confirmed malaria†	42	25	0·60 (0·35–0·99)*
Skin or soft tissue infection	176	136	0·77 (0·61–0·97)*
Urine culture done for clinical indication	80	58	0·73 (0·51–1·03)
Positive urine culture†	41/80 (51·3%)	21/58 (36·2%)	0·51 (0·29–0·89)*
Blood culture done for clinical indication	219	231	1·05 (0·87–1·28)
Positive blood culture†	8/219 (3·7%)	9/231 (3·9%)	1·13 (0·39–3·35)
Started treatment for tuberculosis	49	43	0·88 (0·57–1·35)
Suspected toxicity‡	32	31	0·98 (0·58–1·65)

Data are the number of episodes or n (%) for laboratory tests.

^*p<0·05.

^†Details presented in the appendix.

^‡While receiving study medication (details in the appendix).